Latest Conference Articles

HRQoL Maintained With Added Pembrolizumab in Esophageal Cancer

HRQoL Maintained With Added Pembrolizumab in Esophageal Cancer

January 16th 2021, 6:45pm

ASCO Gastrointestinal Cancers Symposium

In patients with esophageal cancer, chemotherapy with or without added pembrolizumab led to similar health-related quality of life results over 18 weeks, according to findings from the phase 3 KEYNOTE-590 study.

Long-Term Benefit of Pembrolizumab in MSI-H/dMMR mCRC Seen in PFS2, HRQoL

Long-Term Benefit of Pembrolizumab in MSI-H/dMMR mCRC Seen in PFS2, HRQoL

January 16th 2021, 6:00pm

GI Symposium Colorectal Cancer Spotlight

The use of pembrolizumab monotherapy upfront significantly improved progression-free survival while demonstrating superior safety, compared with chemotherapy, in patients with microsatellite-instability high/mismatch repair deficient metastatic colorectal cancer.

Frontline Bemarituzumab Doublet Prolongs Survival in Advanced FGFR2b+ Gastric/GEJ Cancer

Frontline Bemarituzumab Doublet Prolongs Survival in Advanced FGFR2b+ Gastric/GEJ Cancer

January 16th 2021, 5:00pm

ASCO Gastrointestinal Cancers Symposium

In the frontline setting of FGFR2b-positive advanced gastric or gastroesophageal junction adenocarcinoma, the combination of bemarituzumab combined with mFOLFOX6 achieved a 56% reduction in the risk of disease progression or death compared with placebo.

Exploring the Evolving Treatment Landscape for Advanced Hepatocellular Carcinoma

Exploring the Evolving Treatment Landscape for Advanced Hepatocellular Carcinoma

January 16th 2021, 2:00pm

ASCO Gastrointestinal Cancers Symposium

Andrew X. Zhu, MD, PhD, discusses the evolving treatment landscape for patients with hepatocellular carcinoma.

Neoadjuvant Chemo Does Not Impact Surgical Risk in Thoracic Esophageal Cancer

Neoadjuvant Chemo Does Not Impact Surgical Risk in Thoracic Esophageal Cancer

January 15th 2021, 10:30pm

ASCO Gastrointestinal Cancers Symposium

Neoadjuvant chemotherapy regimens were not found to increase the risk for perioperative complications in patients who have potentially resectable advanced thoracic esophageal cancer, according to data from the phase 3 JCOG 1109 trial that were virtually presented at the 2021 Gastrointestinal Cancers Symposium.

Lenvatinib/Pembrolizumab Deemed Safe and Effective in Select GI Cancers

Lenvatinib/Pembrolizumab Deemed Safe and Effective in Select GI Cancers

January 15th 2021, 10:15pm

ASCO Gastrointestinal Cancers Symposium

In multiple gastrointestinal tumor types, the combination of the anti-angiogenic multikinase inhibitor lenvatinib plus the anti-PD-1 antibody pembrolizumab demonstrated promising antitumor activity and a manageable safety profile, according to data presented at the 2021 ASCO Gastrointestinal Cancers Symposium.

Lenvatinib Monotherapy Demonstrates Efficacy in the First Line for HCC

Lenvatinib Monotherapy Demonstrates Efficacy in the First Line for HCC

January 15th 2021, 8:00pm

ASCO Gastrointestinal Cancers Symposium

In a retrospective, real-world analysis of patients with unresectable hepatocellular carcinoma in the United States, investigators observed that lenvatinib alone was effective as first-line treatment.

Anlotinib Improves PFS in RAS/BRAF Wildtype-Positive Metastatic Colorectal Cancer

Anlotinib Improves PFS in RAS/BRAF Wildtype-Positive Metastatic Colorectal Cancer

January 15th 2021, 7:45pm

Treatment with the multi-target tyrosine kinase inhibitor anlotinib led to a significant improvement in progression-free survival along with a tolerable and manageable safety profile in Chinese patients with refractory metastatic colorectal cancer. according to results from the phase 3 ALTER0703 trial.

Nivolumab Shows QoL Improvement in Esophageal and Gastroesophageal Cancers

Nivolumab Shows QoL Improvement in Esophageal and Gastroesophageal Cancers

January 15th 2021, 7:30pm

ASCO Gastrointestinal Cancers Symposium

Esophageal-specific and general quality of life was improved in patients with esophageal/gastroesophageal cancer who received nivolumab in the Checkmate 577 clinical trial, according to subgroup analysis data presented during the 2021 American Society of Clinical Oncology Gastrointestinal Cancers Symposium.

Pembrolizumab/Trastuzumab Regimen Effective in Treating HER2-Positive Advanced Gastric, GEJ Cancer

Pembrolizumab/Trastuzumab Regimen Effective in Treating HER2-Positive Advanced Gastric, GEJ Cancer

January 15th 2021, 7:00pm

ASCO Gastrointestinal Cancers Symposium

The addition of pembrolizumab and trastuzumab to the combination cisplatin plus capecitabine was able to effectively treat HER2-positive advanced gastric and gastroesophageal junction cancer, regardless of PD-L1 expression in the phase 1b/2 PANTHERA trial.